Normalization of Ventricular Repolarization with Flecainide in Long QT Syndrome Patients with SCN5A:DeltaKPQ Mutation

Overview

Journal Ann Noninvasive Electrocardiol

Specialty Cardiology & Vascular Diseases

Date 2001 May 3

PMID 11333173

Citations 36

Authors

J R Windle

R C Geletka

A J MOSS

W Zareba

D L Atkins

Affiliations

Soon will be listed here.

Abstract

Background: The Long QT Syndrome (LQTS) is a genetic channelopathy with life-threatening implications. The LQT3 form of this disease is caused by mutations of the SCN5A sodium-channel gene. A specific mutation, SCN5A:DeltaKPQ, is associated with repetitive reopenings of the sodium channel and prolonged inward current. This dominant inward current is manifest on the electrocardiogram as QT prolongation. Flecainide is a potent blocker of the open sodium channel.

Methods And Results: The effect of flecainide on the duration of the QT-interval and the T-wave morphology was systematically evaluated in five male patients age 2-64 years having the SCN5A:DeltaKPQ mutation. After baseline electrocardiograms were obtained, low-dose oral flecainide was administered for 48 hours. Serial electrocardiograms and blood flecainide levels were obtained during flecainide therapy. The QTc interval decreased on average by 104 ms, from a baseline value of 565 +/- 60 ms to 461 +/- 23 ms (P < 0.04) at a mean flecainide level of 0.28 +/- 0.08 mg/L, with shortening of the QTonset interval (P < 0.003) and normalization of T-wave morphology. The effects of flecainide were compared with oral mexiletine in two patients, with flecainide showing greater QTc shortening and more complete normalization of repolarization. No adverse side effects or proarrhythmia were observed with flecainide in this study.

Conclusion: Low-dose, oral flecainide consistently shortened the QTc interval and normalized the repolarization T-wave pattern in five LQT3 patients with SCN5A:DeltaKPQ mutation. This preliminary study indicates that low-dose flecainide is a promising therapeutic agent for LQTS patients with the SCN5A:DeltaKPQ sodium channel mutation.

Citing Articles

Modeling incomplete penetrance in long QT syndrome type 3 through ion channel heterogeneity: an in silico population study.

Miller J, Moise N, Weinberg S Am J Physiol Heart Circ Physiol. 2022; 324(2):H179-H197.

PMID: 36487185 PMC: 10072004. DOI: 10.1152/ajpheart.00430.2022.

Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.

van der Ree M, van Dussen L, Rosenberg N, Stolwijk N, van den Berg S, van der Wel V Europace. 2022; 24(11):1809-1823.

PMID: 36036670 PMC: 9681134. DOI: 10.1093/europace/euac087.

Effects of Allicin on Late Sodium Current Caused by ΔKPQ-SCN5A Mutation in HEK293 Cells.

Chen Y, Huang Y, Bai J, Liu C, Ma S, Li J Front Physiol. 2021; 12:636485.

PMID: 33854440 PMC: 8039306. DOI: 10.3389/fphys.2021.636485.

Functional modulation of atrio-ventricular conduction by enhanced late sodium current and calcium-dependent mechanisms in Scn5a1798insD/+ mice.

Rivaud M, Marchal G, Wolswinkel R, Jansen J, van der Made I, Beekman L Europace. 2020; 22(10):1579-1589.

PMID: 32778883 PMC: 7544532. DOI: 10.1093/europace/euaa127.

The congenital long QT syndrome Type 3: An update.

Perez-Riera A, Barbosa-Barros R, Raimundo R, da Costa de Rezende Barbosa M, Sorpreso I, de Abreu L Indian Pacing Electrophysiol J. 2017; 18(1):25-35.

PMID: 29101013 PMC: 5840852. DOI: 10.1016/j.ipej.2017.10.011.

References

Chen Q, Kirsch G, Zhang D, Brugada R, Brugada J, Brugada P . Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998; 392(6673):293-6. DOI: 10.1038/32675. View

Roden D, Woosley R . Drug therapy. Flecainide. N Engl J Med. 1986; 315(1):36-41. DOI: 10.1056/NEJM198607033150106. View

Bezzina C, Veldkamp M, van den Berg M, Postma A, Rook M, Viersma J . A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999; 85(12):1206-13. DOI: 10.1161/01.res.85.12.1206. View

Nagatomo T, January C, Makielski J . Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. Mol Pharmacol. 2000; 57(1):101-7. View

Echt D, Liebson P, Mitchell L, Peters R, BARKER A, Arensberg D . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324(12):781-8. DOI: 10.1056/NEJM199103213241201. View

Abbott G, Sesti F, Splawski I, Buck M, Lehmann M, Timothy K . MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999; 97(2):175-87. DOI: 10.1016/s0092-8674(00)80728-x. View

Schwartz P, Priori S, Locati E, Napolitano C, Cantu F, Towbin J . Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995; 92(12):3381-6. DOI: 10.1161/01.cir.92.12.3381. View

MOSS A, Zareba W, Benhorin J, Locati E, Hall W, Robinson J . ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995; 92(10):2929-34. DOI: 10.1161/01.cir.92.10.2929. View

Wang Q, Curran M, Splawski I, Burn T, Millholland J, VanRaay T . Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996; 12(1):17-23. DOI: 10.1038/ng0196-17. View

10.

MOSS A, Schwartz P, Crampton R, Tzivoni D, Locati E, MacCluer J . The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991; 84(3):1136-44. DOI: 10.1161/01.cir.84.3.1136. View

11.

Curran M, Splawski I, Timothy K, Vincent G, Green E, Keating M . A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995; 80(5):795-803. DOI: 10.1016/0092-8674(95)90358-5. View

12.

Bennett P, Yazawa K, Makita N, George Jr A . Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995; 376(6542):683-5. DOI: 10.1038/376683a0. View

13.

Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson J . SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995; 80(5):805-11. DOI: 10.1016/0092-8674(95)90359-3. View

14.

Keating M, Atkinson D, Dunn C, Timothy K, Vincent G, Leppert M . Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991; 252(5006):704-6. DOI: 10.1126/science.1673802. View

15.

An R, Wang X, Kerem B, Benhorin J, Medina A, Goldmit M . Novel LQT-3 mutation affects Na+ channel activity through interactions between alpha- and beta1-subunits. Circ Res. 1998; 83(2):141-6. DOI: 10.1161/01.res.83.2.141. View

16.

Wei J, Wang D, Alings M, Fish F, Wathen M, Roden D . Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation. 1999; 99(24):3165-71. DOI: 10.1161/01.cir.99.24.3165. View

17.

Benhorin J, TAUB R, Goldmit M, Kerem B, Kass R, WINDMAN I . Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?. Circulation. 2000; 101(14):1698-706. DOI: 10.1161/01.cir.101.14.1698. View

18.

Splawski I, Tristani-Firouzi M, Lehmann M, Sanguinetti M, Keating M . Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet. 1997; 17(3):338-40. DOI: 10.1038/ng1197-338. View

19.

Yamagishi H, Furutani M, Kamisago M, Morikawa Y, Kojima Y, Hino Y . A de novo missense mutation (R1623Q) of the SCN5A gene in a Japanese girl with sporadic long QT sydrome. Mutations in brief no. 140. Online. Hum Mutat. 1999; 11(6):481. DOI: 10.1002/(SICI)1098-1004(1998)11:6<481::AID-HUMU12>3.0.CO;2-Q. View

20.

Dumaine R, Wang Q, Keating M, HARTMANN H, Schwartz P, Brown A . Multiple mechanisms of Na+ channel--linked long-QT syndrome. Circ Res. 1996; 78(5):916-24. DOI: 10.1161/01.res.78.5.916. View